Paul Ginocchio is CFO at Augmedix, Inc. (AUGX). They have made 9 open-market trades across 1 company since 2021, most recently 2024-10-02.
CIK 0001826036
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
8 open-market purchases totalling $437K since 2021, against 1 sale. Across 8 scored buys the stock is down 9.7% at ninety days, and 12.5 points behind the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| AUGX | 138,146 | $325K |
Shares reported on the most recent Form 4, priced at the 2024-08-19 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 88% | 38% | 13% |
| Avg Move | +5.9% | +2.4% | -9.7% |
| Alpha | +2.4% | +1.6% | -12.5% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AUGX | SELL | 2024-05-15 | 2024-05-17 | $1.19 | $3K | -14.6% | -34.1% | +94.0% |
| AUGX | BUY | 2023-11-22 | 2023-11-27 | $4.85 | $49K | +10.3% | +14.8% | -14.8% |
| AUGX | BUY | 2022-12-13 | 2022-12-15 | $1.20 | $22K | +14.5% | +36.8% | +16.2% |
| AUGX | BUY | 2022-05-26 | 2022-05-27 | $2.00 | $36K | -15.6% | -24.9% | -21.3% |
| AUGX | BUY | 2021-11-23 | 2021-11-23 | $2.96 | $41K | +18.8% | +9.1% | -22.8% |
| AUGX | BUY | 2021-10-28 | 2021-11-01 | $4.00 | $136K | +1.3% | -16.2% | -34.8% |
| AUGX | BUY | 2021-06-07 | 2021-06-09 | $5.08 | $61K | +6.0% | +0.0% | +0.0% |
| AUGX | BUY | 2021-05-25 | 2021-05-27 | $4.56 | $43K | +6.0% | +0.0% | +0.0% |
| AUGX | BUY | 2021-05-19 | 2021-05-21 | $3.96 | $50K | +6.0% | +0.0% | +0.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.